Evidence map›Paper›PMID 38587783›Full record

ArticleBreast cancer (Tokyo, Japan)2024

Investigation of recurrence prediction ability of EndoPredict

Akira Watanabe, Ryo Tsunashima, Chikage Kato, Sae Kitano, Saya Matsumoto, Yoshiaki Sota, Midori Morita, Koichi Sakaguchi, Yasuto Naoi

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akira WatanabeDepartment of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0003-0496-5945
Ryo TsunashimaDepartment of Breast and Endocrine Surgery, Rinku General Medical Center, Osaka, Japan. r-tsunashima@rgmc.izumisano.osaka.jp.ORCID http://orcid.org/0000-0003-2663-0142
Chikage KatoDepartment of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Sae KitanoDepartment of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID http://orcid.org/0009-0008-6896-3088
Saya MatsumotoDepartment of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yoshiaki SotaDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID http://orcid.org/0000-0001-5963-652X
Midori MoritaDepartment of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0003-4083-4432
Koichi SakaguchiDepartment of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yasuto NaoiDepartment of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6090-0137

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndoPredict

methodsWe analyzed the publicly available data of 431 node-negative and 270 node-positive patients with luminal breast cancer who received endocrine therapy alone. We evaluated the prognostic value of EP using microarray data from FF tissues. Next, we created an algorithm to calculate EP risk score using microarray data from FFPE tissues. We examined the correlation coefficient of EP risk score and concordance rate of EP risk high/low using microarray data from FFPE/FF tissue pairs in a validation set of 39 patients.

resultsIn 431 node-negative patients, the distant recurrence-free survival (DRFS) rate was significantly worse in those with high EP risk scores (P = 3.68 × 10

conclusionsEP using microarray data from FF tissues was useful in predicting distant recurrence risk in luminal breast cancer, and EP might be utilized in microarray data from FFPE tissues.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoplasm Recurrence, LocalParaffin EmbeddingReceptors, EstrogenAdultAgedBiomarkers, TumorFemaleGene Expression ProfilingHumansMiddle AgedOligonucleotide Array Sequence AnalysisPrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenBreast cancerEndoPredict®LuminalMicroarray data

Identifiers

PMID38587783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.